Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron extended its 2020 procurement agreement with BARDA to supply additional doses of Inmazeb, its FDA-approved Ebola treatment, to the U.S. government through 2031 for approximately $270 million. Separately, Regeneron is adding its investigational maftivimab monotherapy to the WHO-sponsored PARTNERS trial as a potential treatment for Bundibugyo virus, which is driving the current outbreak in the Democratic Republic of the Congo and has no approved treatment options.
Key figures
- Drug Name
- Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)
- Deal Value Usd
- 270000000
- Phase Of Trial
- PARTNERS trial (maftivimab monotherapy addition)
- Delivery Through
- 2031
- Palm Trial Patients
- 681
- Mortality Reduction
- approximately 55 percent in low viral load patients
- Donated Doses Commitment
- up to 500 doses to WHO (September 2025)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.